TICKERNERD
Menu
OCGNOCGNHealthcare · Biotechnology

OCGN Stock Forecast: Ocugen, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.02
−0.49% on the day

The 6 Wall Street analysts covering Ocugen, Inc. hold a median 12-month price target of $11 — +929.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$345.9M
Ticker Nerd rank
22 / 100
Median analyst target
$11
Analysts covering
6
Revenue$1.5M+8.4% y/y
Operating income−$16.4M
Net income−$24.9M
Free cash flow−$12.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−24.4%
1M
−25.5%
YTD
−24.4%
1Y
−4.7%
From 52W high
−58.9%
From 52W low
0.0%
$1.02
$2.48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OCGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ocugen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
22 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
73
Size
59
Value
49
Volatility
47
Momentum
44
Revisions
38
Growth
29
Quality
9
Issuance
9

Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OCGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OCGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26OCGNHigh $22Median $11Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $8Median $11High $22

The green dot is the last close — the median target sits +929.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.MaintainsBuy$10 → $9.50
27 May 2026Canaccord GenuityMaintainsBuy$12 → $11
27 May 2026Canaccord GenuityMaintainsBuy—
25 Mar 2026Chardan CapitalMaintainsBuy—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
17 Mar 2026Canaccord GenuityInitiatesBuy—
11 Mar 2026OppenheimerInitiatesOutperform—
5 Mar 2026Chardan CapitalMaintainsBuy—
20 Jan 2026Chardan CapitalMaintainsBuy—
19 Sept 2025Chardan CapitalMaintainsBuy—
4 Aug 2025Chardan CapitalMaintainsBuy—
24 June 2025Chardan CapitalMaintainsBuy—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
12 May 2025Chardan CapitalMaintainsBuy—
12 May 2025HC Wainwright & Co.MaintainsBuy—
6 Mar 2025Chardan CapitalMaintainsBuy—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Feb 2025Chardan CapitalMaintainsBuy—
13 Feb 2025HC Wainwright & Co.MaintainsBuy—
23 Jan 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OCGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OCGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Ocugen, Inc. returned −4.7% against +17.5% for the S&P 500, dividends included.

OCGN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26OCGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OCGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

Ocugen, Inc. (OCGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.5×

Cheaper than 89% of US stocks

Price / sales
75.5×

Cheaper than 4% of US stocks

Price / book
−21.0×

Cheaper than 98% of US stocks

EV / EBITDA
−5.0×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
8.4%

Higher than 48% of US stocks

Earnings growth (YoY)
8.4%

Higher than 46% of US stocks

Gross margin
—
Operating margin
−1105.1%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
557.7%

Higher than 99% of US stocks

Return on assets
−48.4%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ocugen, Inc. (OCGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ocugen, Inc. has a market value of $345.9M and an enterprise value of $333.8M.

  • Revenue in the twelve months to 30 June 2026: $4.6M. The latest quarter grew 8.4% year on year.

  • Net income over the same four quarters: −$81.8M, a −1786.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.25.

  • Free cash flow in the twelve months to 30 June 2026: −$61.0M.

  • Shares outstanding: 339.0M.

  • Trailing P/E: −4.5×; forward P/E: −3.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Ocugen, Inc. employs 116 people — $39K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

OCGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OCGNOcugen, Inc.$345.9M
22
XFORX4 Pharmaceuticals, Inc.$347.0M
62
IPSCCentury Therapeutics, Inc.$348.5M
39
DMACDiaMedica Therapeutics, Inc.$348.9M
47
EYPTEyePoint, Inc.$350.2M
14
SIONSionna Therapeutics, Inc.$350.3M
26
LXEOLexeo Therapeutics, Inc.$333.7M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ocugen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OCGN news & analysis

Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical

Seeking Alpha · 11 Sept 2026positive

Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—in ophthalmology. The company has a Buy rating, with upcoming catalysts including Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and an FDA-cleared Phase 3 trial for OCU410.

Why it matters — A Stargardt-disease gene therapy data catalyst in Q3 is considered critical for Ocugen's near-term outlook, so OCGN watchers would track these upcoming trial milestones closely.

What's Happening With Ocugen Stock Thursday?

Benzinga · 10 Sept 2026neutral

Ocugen shares remained flat Thursday morning as investors continued to weigh disappointing interim clinical trial data. The stock price stayed steady amid ongoing assessment of the company's trial results.

Why it matters — A watcher of Ocugen would care because the flat stock movement reflects investor reaction to underwhelming interim clinical data, a key development for the company's pipeline.

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Zacks Investment Research · 2 Sept 2026positive

Ocugen has advanced its gene therapy OCU410 into Phase III for geographic atrophy, with study plans aligned with the FDA. The company expects to file a Biologics License Application (BLA) for OCU410 in 2028.

Why it matters — This milestone moves Ocugen's lead gene therapy candidate into late-stage development with FDA-aligned plans, signaling pipeline progress toward a potential regulatory submission in 2028.

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewsWire · 1 Sept 2026positive

Ocugen announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410, its modifier gene therapy candidate for geographic atrophy secondary to dry age-related macular degeneration. The company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway.

Why it matters — This milestone advances Ocugen's lead gene therapy program into late-stage clinical testing and, with the RMAT designation, may accelerate its path toward potential regulatory review.

Ocugen to Participate in Upcoming September Investor and Industry Conferences

GlobeNewsWire · 25 Aug 2026neutral

Ocugen announced it will present on its modifier gene therapy platform at investor and industry conferences scheduled for September 2026. The announcement was made on August 25, 2026.

Why it matters — The company's participation provides Ocugen watchers with an opportunity to learn more about its modifier gene therapy platform through upcoming conference presentations.

FAQ

Frequently asked questions about OCGN stock

What is the OCGN stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Ocugen, Inc. have a median 12-month price target of $11, with estimates ranging from $8 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OCGN stock a buy right now?

Of the 6 analysts covering Ocugen, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocugen, Inc. 22 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OCGN?

As at 12 Sept 2026, Ocugen, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).

Will OCGN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +929.4% from the last close, and Ticker Nerd's factor model ranks Ocugen, Inc. 22 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OCGN stock forecast for 2030?

No analyst covering Ocugen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $22 over the next 12 months.

How has OCGN stock performed over the past year?

Ocugen, Inc. returned -4.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ocugen, Inc. do?

Ocugen Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for blindness diseases and other serious ocular conditions.

What is the latest news on OCGN?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical". Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—in ophthalmology. The company has a Buy rating, with upcoming catalysts including Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and an FDA-cleared Phase 3 trial for OCU410.

Company

About Ocugen, Inc.

Ocugen Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for blindness diseases and other serious ocular conditions. Its current programs center on a modifier gene therapy platform designed to address inherited retinal diseases and multifactorial eye disorders, including retinitis pigmentosa, Stargardt disease, and geographic atrophy. The company also works on cell therapy and vaccine-related research through selective programs and collaborations, reflecting a broader focus on unmet medical needs in ophthalmology and infectious disease. Ocugen’s pipeline includes product candidates under clinical development rather than marketed therapies, so its role in the market is primarily tied to research, development, and partnership-driven innovation. Headquartered in Malvern, Pennsylvania, Ocugen Inc. operates as a biotechnology company concentrated on advancing treatments for patients with limited current options.

CEO Dr. Shankar Musunuri M.B.A., Ph.D. · 116 employees · United States · https://www.ocugen.com